Drug resistance mutations in HIV-1. 2003

Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA.

The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group is a volunteer panel of experts that meets regularly to review and interpret new data on HIV-1 resistance. The focus of the group is to identify mutations associated with clinical resistance to HIV-1. These mutations have been identified by 1 or more of the following criteria: (1) in vitro passage experiments or validation of contribution to resistance by using site-directed mutagenesis; (2) susceptibility testing of laboratory or clinical isolates; (3) genetic sequencing of viruses from patients in whom the drug is failing; (4) correlation studies between genotype at baseline and virologic response in patients exposed to the drug. Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010597 Pharmacogenetics A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION). Pharmacogenomics
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
November 2013, The Journal of infectious diseases,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
January 2009, PloS one,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
October 2022, Topics in antiviral medicine,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
January 2014, Topics in antiviral medicine,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
December 2016, Topics in antiviral medicine,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
January 2015, Topics in antiviral medicine,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
November 2011, Topics in antiviral medicine,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
September 2019, Topics in antiviral medicine,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
January 2020, Archives of virology,
Victoria A Johnson, and Françoise Brun-Vézinet, and Bonaventura Clotet, and Brian Conway, and Richard T D'Aquila, and Lisa M Demeter, and Daniel R Kuritzkes, and Deenan Pillay, and Jonathan M Schapiro, and Amalio Telenti, and Douglas D Richman, and
October 1997, AIDS (London, England),
Copied contents to your clipboard!